Generic Name and Formulations:
Sacrosidase 8500 IU/mL; oral soln.
QOL Medical, LLC
Indications for SUCRAID:
Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency.
<5months: not recommended. ≥5months: ≤15kg: 8500 IU per meal or snack. >15kg: 17000 IU per meal or snack. Dilute dose with 2–4 ounces of water, milk, or infant formula. Serve cold or at room temp; do not warm up or heat liquid before or after addition of Sucraid. Give half the dose at the beginning of the meal/snack and the remainder during meal/snack.
Hypersensitivity to yeast, glycerin, papain.
Administer initial dose near facility where acute hypersensitivity reactions can be treated; discontinue if hypersensitivity occurs. Diabetes. Evaluate for dietary starch restriction. Secondary disaccharidase deficiencies. Pregnancy (Cat. C).
Do not reconstitute or consume with fruit juice; acidity reduces enzyme activity.
Abdominal pain, GI upset, constipation, insomnia, headache, nervousness, dehydration; rare: wheezing.
Soln (118mL)—2 bottles (w. measuring scoops)
Neurology Advisor Articles
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- OnabotulinumtoxinA for Post-Stroke Spasticity: Treatment Strategies and Limitations
- Tau Associated With Loss of Anterior Temporal White Matter Integrity
- Location Probability Learning Unimpaired in Parkinson Disease
- Prenatal Tdap Vaccination Not Linked to Autism Risk
- AMA Adopts Policy to Advance Gender Equity in Medicine